PharmaGap Inc., a biotechnology company, engages in drug development and out-licensing of drug compounds in Canada. The company focuses on the development of peptide therapeutics for the treatment of cancer and other human disease conditions. Its lead drug compound, GAP-107B8, is in the pre-clinical testing stage for the treatment of cancer targeting Protein Kinase C (PKC). The company was founded in 1999 and is based in Ottawa, Canada.
(GAP:TSX Venture Exchange NEX)
100 Sussex Drive
Ottawa, ON K1A 0R6
|No competitor information is available for GAP.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PHARMAGAP INC, please visit www.pharmagap.com. Company data is provided by Capital IQ. Please use this form to report any data issues.